Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer - Takeaways - MDSpire

Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer

  • By

  • Hubin Xu

  • Mengyu Zhang

  • Huinan Zhu

  • Haimin Jiang

  • Wenjie Zeng

  • Xiaoyan Chen

  • Huafeng Shou

  • Lingqian Zhao

  • July 3, 2026

  • 0 min

Share

  • 1

    A retrospective study identified five independent risk factors for postmenopausal endometrioid endometrial carcinoma: BMI, CA125, HE4, PLR, and ALB.

  • 2

    The study enrolled 311 patients, including 119 with benign endometrial diseases and 192 with endometrioid carcinoma.

  • 3

    A clinical risk prediction model was developed, achieving an area under the curve (AUC) of 0.936, indicating strong predictive performance.

  • 4

    The model demonstrated a specificity of 89.1% and a sensitivity of 90.1% at the optimal Youden index.

  • 5

    An online calculator was created to facilitate dynamic clinical risk predictions for postmenopausal endometrioid endometrial carcinoma.

Original Source(s)

Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer

  • by Hubin Xu, Mengyu Zhang, Huinan Zhu, Haimin Jiang, Wenjie Zeng, Xiaoyan Chen, Huafeng Shou, Lingqian Zhao

  • July 3, 2026

Related Content

Habitat-based amide proton transfer-weighted MRI model for predicting BRAF mutation and prognostic stratification in rectal cancer

Early multi-cancer detection using liquid biopsy: emerging biomarkers and clinical strategies

Business-in-Brief: June 2026

This month’s analytical science business news: Merck’s Bio-Techne acquisition, plus major ASMS product launches

  • July 2, 2026

  • 5 min